Android app on Google Play

GlaxoSmithKline (GSK) Withdrawals FDA App for Breast Cancer Treatment Tykerb

July 12, 2012 10:18 AM EDT Send to a Friend
GlaxoSmithKline plc (NYSE: GSK) said it has withdrawn a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Tykerb (lapatinib) in combination with trastuzumab for the treatment of patients with HER2 (ErbB2)-positive metastatic breast cancer who have received prior trastuzumab therapy. Regulatory reviews are ongoing in the European Union and other regions.

“Our discussions with FDA highlighted questions that could not be addressed with the data currently available.” said Rafael Amado, Head of Oncology R&D for GlaxoSmithKline. “We have decided to withdraw our application in the US with the intent to wait for ongoing studies testing the combination of lapatinib with trastuzumab.”




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment